Sonoma Pharmaceuticals, Inc.

During the quarter ended September 30, 2026, no director or officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Recent Distribution and Co-Development Agreements

In September 2026, we were engaged by a U.S.-based professional skincare company to participate in a paid co-formulation project evaluating the integration of specialized skincare ingredients with our HOCl technology platform.

In July 2026, we entered into a new commercial relationship with a U.S.-based wound-care company that specializes in innovative bandage products.

In November 2026, we entered into a new U.S. distribution relationship for HOCl products in the senior care market.

Termination of Master Supply Agreement

On June 28, 2026, we sent Wellspring Pharmaceutical Corporation a notice indicating our intent to renegotiate certain commercial terms of the Master Supply Agreement, dated January 29, 2025, for the sale of Microcyn technology-based products to retailers in the United States (as amended, the “Agreement”) to align the commercial terms with the operating requirements and economics of the relationship. The parties were unable to negotiate mutually acceptable terms.

On November 6, 2026, we received written notice from WellSpring Pharmaceutical Corporation regarding termination. Pursuant to the terms of the Agreement, the termination will become effective following a 90-day notice period on February 4, 2027.